Next Generation Pain Relief Without Addiction
Our lead program targets a the peripheral kappa opioid receptor (KOR) using cyclic peptides inspired by the natural ligand dynorphin A. These molecules are designed to provide potent analgesia without crossing the blood-brain barrier—dramatically reducing the risk of addiction, dysphoria, and sedation. Pepdura expects to nominate a clinical candidate by Q4 2025 and begin pre-IND development soon after.
The Pain Market
​
Pepdura is set to revolutionize the opioid market, projected to grow annually by 5.2% and reach a valuation of USD 43.3 billion by 2023. Our innovative drugs promise effective pain relief with fewer side effects and a lower risk of addiction, aligning with the market's demand for safer alternatives. The enhanced safety and reduced addiction potential of our products are expected to further stimulate growth in this sector.
Leveraging Pepdura's cutting-edge technologies, we are on a path to develop therapies for numerous diseases that currently lack sufficient clinical solutions. Our commitment to innovation and patient safety positions us to make significant contributions to healthcare and improve treatment options for underserved conditions.